Financial Royalty Assets - Narrative (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
|
| Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
| Total current and non-current financial royalty assets, net | $ 17,082,171 | $ 17,082,171 | $ 17,062,868 | |||
| Non-cash impairment charges | 0 | $ 69,400 | $ 0 | 69,443 | $ 0 | |
| Unapproved Assets | ||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
| Financing receivable, unapproved financial assets held at cost | 1,600,000 | 1,600,000 | ||||
| Financial Royalty Asset, Fexalimab | ||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | ||||||
| Total current and non-current financial royalty assets, net | $ 522,600 | $ 522,600 | ||||
| X | ||||||||||
- Definition Financing Receivable, Unapproved Financial Assets Held At Cost No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of impairment loss for asset. Includes, but is not limited to, tangible and intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|